Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Average Recommendation of “Buy” from Brokerages

Centessa Pharmaceuticals plc (NASDAQ:CNTA) has received a consensus rating of “Buy” from the seven ratings firms that are covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have covered the stock in the last year is $25.83.

Several equities analysts have issued reports on the company. TD Cowen began coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating on the stock. Guggenheim raised their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th.

Centessa Pharmaceuticals Price Performance

CNTA stock opened at $16.46 on Wednesday. The business has a 50 day moving average price of $16.79 and a 200 day moving average price of $14.92. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market cap of $2.17 billion, a price-to-earnings ratio of -10.76 and a beta of 1.53. Centessa Pharmaceuticals has a fifty-two week low of $7.38 and a fifty-two week high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.05. Equities research analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, General Counsel Iqbal J. Hussain sold 6,000 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the completion of the transaction, the general counsel now directly owns 118,265 shares of the company’s stock, valued at approximately $1,808,271.85. This represents a 4.83 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $18.46, for a total value of $1,615,176.16. Following the completion of the sale, the chief executive officer now owns 575,661 shares in the company, valued at approximately $10,626,702.06. This trade represents a 13.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 392,484 shares of company stock valued at $6,723,523 in the last ninety days. Insiders own 11.59% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CNTA. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares during the period. GAMMA Investing LLC increased its holdings in Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after buying an additional 1,509 shares in the last quarter. Quarry LP lifted its position in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after acquiring an additional 3,108 shares during the period. Sandia Investment Management LP acquired a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter valued at approximately $90,000. Finally, Fred Alger Management LLC purchased a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth approximately $99,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.